论文部分内容阅读
目的评价阿奇霉素联合头孢曲松钠治疗儿童难治性肺炎支原体肺炎(RMPP)的疗效及安全性。方法 84例收治入院的RMPP儿童,以入院时间按1:3比例随机分为常规单药组(静脉滴注阿奇霉素,n=21)和联合用药组(静脉滴注阿奇霉素+头孢曲松钠,n=63)。以发热持续时间、咳嗽缓解时间和住院时间及肺部炎症总吸收率评估临床疗效,并观察不良反应。结果治疗后,联合用药组和常规单药组的总有效率分别为84.13%和57.14%,差异有统计学意义(P<0.05)。与常规单药组相比,联合用药组发热持续时间、咳嗽缓解时间及住院时间等明显较短(P<0.05);与常规单药组相比,联合用药组炎症总吸收率更高(73.02%对38.10%,P<0.05)。两组均无严重不良反应发生。结论阿奇霉素联合头孢曲松钠治疗儿童RMPP效果明显,不良反应少,安全可行。
Objective To evaluate the efficacy and safety of azithromycin combined with ceftriaxone sodium in the treatment of refractory mycoplasma pneumoniae pneumonia (RMPP) in children. Methods 84 children admitted to hospital for RMPP were randomly divided into conventional single drug group (intravenous azithromycin, n = 21) and combination group (intravenous azithromycin + ceftriaxone sodium, n = 63). The duration of fever, cough relief time and hospital stay and lung inflammation total absorption rate to assess the clinical efficacy, and observe the adverse reactions. Results After treatment, the total effective rate was 84.13% in the combination group and 57.14% in the conventional monotherapy group, the difference was statistically significant (P <0.05). Compared with the conventional single drug group, the duration of fever, cough relief time and hospital stay were significantly shorter in the combination group (P <0.05), and the total inflammatory response rate in the combination group was higher than that in the conventional single drug group (73.02 % Vs 38.10%, P <0.05). No serious adverse reactions occurred in both groups. Conclusion Azithromycin combined with ceftriaxone sodium treatment of children with RMPP obvious effect, less adverse reactions, safe and feasible.